Performance and diagnostic usefulness of commercially available enzyme linked immunosorbent assay and rapid kits for detection of HIV, HBV and HCV in India by Susmita Maity et al.
Maity et al. Virology Journal 2012, 9:290
http://www.virologyj.com/content/9/1/290RESEARCH Open AccessPerformance and diagnostic usefulness of
commercially available enzyme linked
immunosorbent assay and rapid kits for
detection of HIV, HBV and HCV in India
Susmita Maity, Srijita Nandi, Subrata Biswas, Salil Kumar Sadhukhan and Malay Kumar Saha*Abstract
Background: HIV, HBV and HCV pose a major public health problem throughout the world. Detection of infection
markers for these agents is a major challenge for testing laboratories in a resource poor setting. As blood
transfusion is an important activity saving millions of live every year, it also carries a risk of transfusion transmissible
infections caused by these fatal blood borne pathogens if the quality of testing is compromised. Conventional
ELISA is regarded as the mostly used screening technique but due to limitations like high cost, unavailability in
many blood banks and testing sites, involvement of costly instruments, time taking nature and requirement of
highly skilled personnel for interpretation, rapid tests are gaining more importance and warrants comparison of
performance.
Results: A comparative study between these two techniques has been performed using commercially available
diagnostic kits to assess their efficacy for detection of HIV, HBV and HCV infections. Rapid kits were more efficient in
specificity with synthetic antigens along with high PPV than ELISA in most cases. Comparison between different
ELISA kits revealed that Microlisa HIV and Hepalisa (J. Mitra & Co. Pvt. Ltd.); ERBA LISA HIV1 + 2, ERBA LISA Hepatitis
B and ERBA LISA HCV (Transasia Bio-medicals Ltd.) gives uniform result with good performance in terms of
sensitivity, specificity, PPV, NPV and efficiency, whereas, Microlisa HCV (J. Mitra & Co. Pvt. Ltd.), Microscreen HBsAg
ELISA and INNOVA HCV (Span Diagnostics Ltd.) did not perform well. Rapid kits were also having high degree of
sensitivity and specificity (100%) except in HIV Comb and HCV Comb (J. Mitra & Co. Pvt. Ltd.). The kit efficiency
didn’t vary significantly among different companies and lots in all the cases except for HCV ELISA showing
statistically significant variation (p < 0.01) among three kit types.
Conclusions: ELISA is a good screening assay for markers of HIV, HBV and HCV infections. Rapid tests are useful for
further detection of false positive samples. ELISA seems the appropriate assay in blood bank. For availability of
quality commercial diagnostic assays, evaluation of kit may be helpful.
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Human immunodeficiency virus (HIV), hepatitis B virus
(HBV) and hepatitis C virus (HCV) are the most threaten-
ing blood borne pathogens which have proved to be major
risk factors for transfusion transmissible infections in
human population. Blood transfusion is an important ac-
tivity that saves millions of live every year [1]. But still it
carries risk of transfusion associated diseases like hepatitis,
acquired immunodeficiency syndrome (AIDS) and some
other blood borne sexually transmitted diseases [2,3].
About 350 millions of patients are suffering from hepatitis
B all over the world [3,4]. In India, 2–3 million individuals
have been reported to be infected with HIV and transmis-
sion of this infection has been shown to be strongly asso-
ciated with other sexually transmitted infections (STIs)
and sexual behavior [5]. Hepatitis B and C causes severe
complications after transfusion of contaminated blood
[6-12]. It has been estimated that the global prevalence
of Hepatitis C virus (HCV) infection is around 2%, with
170 million persons chronically infected with the virus
and 3 to 4 million persons newly infected each year [13].
Transmission of hepatitis C through intravenous and per-
cutaneous drug usage is a significant problem in northeast
India and the prevalence of HCV was an alarming 92%
among 77 IV drug abusers from Manipur [14]. In two
studies from Mumbai the prevalence of HCV in multiple
transfused thallasemics was 16.7% and 17.5% respectively
[15,16]. In multi-transfused children with varied diagnosis,
the prevalence of HCV was 13% reported from Kolkata
[17]. Occurrence of HIV has also been increased signifi-
cantly in the developing countries [18,19]. So there is an
acute need for testing of markers for HIV1 and 2, Hepa-
titis B, Hepatitis C and other sexually transmitted diseases
(STD). Conventional enzyme linked immunosorbent assay
(ELISA) is most referred screening technique [3] and pos-
sess an accuracy of about 99.9% [20,21] with improved
sensitivity but some of the kits reported to have lower spe-
cificity [22]. Additionally, the method is laborious, time
taking and needs proficient skill to perform and also not
available in many blood bank/testing sites. Comparatively,
rapid tests are easier, quicker and require less skill to per-
form. There is no requirement of any instruments also.
Present study deals with the evaluation of performance as
well as usefulness of both ELISA and rapid assay for de-
tection of three major blood borne pathogens namely
HIV, HBV and HCV using separate panel-sera for each.
Three most commonly available ELISA and rapid kits
(three lots for each kit- type) were evaluated of which two
ELISA and rapid kits each were of same manufacturer.
Results
In current study, 300 samples (100 samples/lot, 3 lots
evaluated for each kit) were tested for each set ofevaluation of both ELISA and rapid kits for HIV, hepa-
titis B surface antigen (HBsAg) and HCV and the results
were summarized in Table 1. It is evident that Microlisa
HIV, ERBA LISA HIV 1 + 2, ERBA LISA Hepatitis B,
ERBA LISA HCV and Hepalisa - HBsAg gives uniform
results by identifying all panel samples correctly with
good performance (100% sensitivity, specificity, PPV,
NPV and efficiency) as compared to other ELISA kits
(Table 2). Enzaids HIV 1 + 2 also had similar perform-
ance except in one lot where specificity was 98.9%. Per-
formance of Microlisa HCV, Microscreen HBsAg ELISA
and INNOVA HCV are not satisfactory with higher
number of false positive results (Table 1) and subsequent
reduced specificity, but all of the ELISA kits are capable
of detecting positive samples correctly that also reflected
in kit sensitivity (100%). It is also evident from the
present report that rapid kits have good specificity and
sensitivity (100%) except HIV Comb (mean sensitivity
98.3%) and HCV Comb (mean sensitivity 95.5%) show-
ing poor performance (Table 3) with some false negative
results for low positive sera. In each panel of HIV, HBV
and HCV four low positive sera were included. HIV
comb was unable to detect 2 low positives in one lot,
whereas, HCV comb gives false negatives in two lots
(2 false negatives in lot 1 and 4 false negatives in lot 2; all
were low positive sera).
Present study revealed a better performance in rapid
kits of Standard Diagnostics Inc. and Span Diagnostics
Ltd. in terms of specificity and sensitivity than J. Mitra &
Co. Pvt. Ltd. except for HBsAg rapid kits where per-
formance of all kits is equally good. Mean specificity of
HIV and HBsAg ELISA kits manufactured by SPAN
Diagnostics Ltd. are relatively lower (<100%) than Transa-
sia Biomedicals Ltd. and J. Mitra and Co. Pvt. Ltd. (100%)
except for HCV ELISA kits where lower specificity with
many false positives found in Microlisa HCV. A total of
20 false positives with 88.1% mean specificity observed
in Microlisa HCV which is quite poor performance in
terms of detection of infection. Innova HCV and
Microscreen HBsAg ELISA also had shown false posi-
tive results. A 2-way ANOVA test also used to assess
the statistical variability in efficiency values due to
‘companies’ and ‘lots’ and this statistical analysis de-
cipher that the efficiency of three commercially avail-
able rapid kits of all three categories (HIV, HBsAg and
HCV) didn’t vary significantly (p > 0.05) among the
companies as well as in the lots. Same observation also
recorded in HIV and HBsAg ELISA kits where no sig-
nificant variation found in efficiency of three kit types
and among the lots (p > 0.05). Whereas, in HCV ELISA,
kit efficiency varies significantly among three different
kit types (p < 0.01, F value =20.0, df: η1 = 2, η2 = 4) but
no significant variation found in lots.
Table 1 Performance of HIV, HBsAg and HCV kits with known Panel Sera
Test
parameter







Lot ELISA Rapid Test
J Mitra & Co.
Pvt Ltd
SPAN Diagnostics Ltd. TransasiaBio
medicals Ltd.






Positive Negative Positive Negative Positive Negative Positive Negative positive Negative Positive Negative
HIV 100 40 60 LOT:1 40 60 42 58 40 60 40 60 40 60 40 60
LOT:2 40 60 40 60 40 60 40 60 40 60 40 60
LOT:3 40 60 40 60 40 60 38 62 40 60 40 60
HBsAg 100 40 60 LOT:1 40 60 42 58 40 60 40 60 40 60 40 60
LOT:2 40 60 40 60 40 60 40 60 40 60 40 60
LOT:3 40 60 42 58 40 60 40 60 40 60 40 60
HCV 100 44 56 LOT:1 51 49 50 50 44 56 42 58 44 56 44 56
LOT:2 51 49 46 54 44 56 40 60 44 56 44 56
LOT:3 50 50 46 54 44 56 44 56 44 56 44 56















Table 2 Performance characteristic of HIV, HBsAg and HCV ELISA kits used for comparative evaluation
Test
Parameter
Kit Company Lot Kit Performance
Sensitivity Specificity PPV NPV Efficiency
(%) %Mean (95%CI) (%) %Mean (95%CI) (%) %Mean (95%CI) (%) %Mean (95%CI) (%) %Mean (95%CI)
HIV J. Mitra & Co. Pvt. Ltd. 1 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100
SPAN Diag. Ltd. 1 100 100 (100–100) 96.7 98.9 (96.8-100.9) 95.2 98.4 (95.8-101.0) 100 100 (100–100) 98.0 99.3 (98.3-100.4)
2 100 100 100 100 100
3 100 100 100 100 100
Transasia Bio medicals Ltd. 1 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100
HBsAg J. Mitra & Co.Pvt. Ltd. 1 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100
SPAN Diag. Ltd. 1 100 100 (100–100) 96.7 97.8 (96.0 −99.6) 95.2 96.8 (94.2 −99.4) 100 100 (100–100) 98.0 98.7 (97.6-99.7)
2 100 100 100 100 100
3 100 96.7 95.2 100 98.0
Transasia Bio medicals Ltd. 1 100 100 (100–100) 100 100 (100 −100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100
HCV J. Mitra & Co.Pvt. Ltd. 1 100 100 (100–100) 87.5 88.1 (87.1 −89.1) 86.3 86.9 (86.0 −87.8) 100 100 (100–100) 93.0 93.3 (92.8-93.9)
2 100 87.5 86.3 100 93.0
3 100 89.3 88.0 100 94.0
SPAN Diag. Ltd. 1 100 100 (100–100) 89.3 94.0 (90.2 −97.8) 88.0 93.1 (89.0 −97.2) 100 100 (100–100) 94.0 96.7 (94.5-98.8)
2 100 96.4 95.7 100 98.0
3 100 96.4 95.7 100 98.0
Transasia Bio medicals Ltd. 1 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100















Table 3 Performance characteristic of HIV, HBsAg and HCV rapid kits used for comparative evaluation
Test
Parameter
Kit Company Lot Kit Performance
Sensitivity Specificity PPV NPV Efficiency
(%) %Mean (95%CI) (%) %Mean(95%CI) (%) %Mean (95%CI) (%) %Mean (95%CI) (%) %Mean (95%CI)
HIV J. Mitra & Co. Pvt. Ltd. 1 100 98.3 (95.7-101.0) 100 100 (100–100) 100 100 (100–100) 100 98.9 (97.2-100.6) 100 99.3 (98.3-100.4)
2 100 100 100 100 100
3 95.0 100 100 96.8 98.0
SPAN Diag. Ltd. 1 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100
Standard. Diag. Inc. 1 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100
HBsAg J. Mitra & Co. Pvt. Ltd. 1 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100
SPAN Diag. Ltd. 1 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100
Standard. Diag. Inc. 1 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100
HCV J. Mitra & Co. Pvt. Ltd. 1 95.5 95.5 (91.2-99.7) 100 100 (100–100) 100 100 (100–100) 96.6 96.6 (93.5-99.8) 98.0 98.0 (96.1-99.8)
2 90.9 100 100 93.3 96.0
3 100 100 100 100 100
SPAN Diag. Ltd. 1 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100
Standard. Diag. Inc. 1 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100) 100 100 (100–100)
2 100 100 100 100 100
3 100 100 100 100 100















Maity et al. Virology Journal 2012, 9:290 Page 6 of 9
http://www.virologyj.com/content/9/1/290Discussion
Detection of HIV, HBV and HCV infections and diagnosis
is mainly based on immunological assays among which
ELISA and rapid tests are most common and widespread
methods [23,24]. An important problem encountered at
this point is the discordance between the results of two
assays [22], which can be resolved depending on the
availability of suitable kits. Hence, kit evaluation gains
importance for determining the diagnostic kits of better
performance. Though ELISA assay shows a high degree
of sensitivity, it is costly and time taking job, so rapid
tests become a good alternative for ELISA in blood banks
and other testing laboratories in course of time [25].
Moreover, uses of synthetic antigens in some rapid kits
have increased the specificity [25]. Performance of rapid
test would be satisfactory with a high PPV and lower
degree of false negatives [23].
This study revealed a higher PPV in rapid tests along
with better efficiency (100%) than ELISA in most of the
cases except for HIV comb and HCV Comb- J. Mitra &
Co. Pvt. Ltd. revealed 99.3% and 98.0% efficiency respect-
ively. Although for a diagnostic test, the PPV and NPV
will change as the prevalence of the target condition
changes in the tested population. Thus, the J. Mitra &
Co. HCV ELISA kit would project a PPV of 6.6%, 41.7%
and 22.2% for global population with 0.8% HIV, 5% HBV
and 2% HCV prevalence respectively. 4th generation
HCV-comb with unique combination of modified HCV
antigens have failed to show better result in this study
with lowest efficiency and sensitivity (95.5%) than two
other HCV rapid kits, therefore use of this type of kit in
blood banks should be avoided.
HIV comb with recombinant antigens have also shown
much less sensitivity (98.3%) than other HIV rapid kits
evaluated, whereas, the uses of synthetic peptides along
with recombinant antigen have given an added advan-
tage to Combaids RS Advantage (22) with a better per-
formance than HIV-comb. SD BIOLINE HIV 1/2 3.0
Rapid have also shown better result with 100% sensitivity.
So, considering these parameters, HIV comb is not an
appropriate kit for blood banks and ICTCs in terms of
its lower sensitivity than other HIV rapid kits.
The HIV ELISA kits manufactured by SPAN Diagnostics
Ltd. were revealed poor performance than the other HIV
ELISA kits in terms of specificity and overall efficiency of
those kits was also poor (99.3%). This was also true for
Microscreen HBsAg ELISA kits (98.7%) but, in case of
HCV ELISA kits, HCV Microlisa were also shown lower ef-
ficiency (93.3%) along with INNOVA HCV ELISA (96.7%).
Present study also showed lot to lot variation in per-
formance of some kits. Mostly it was found in HCV
Microlisa, Enzaids HIV 1 + 2 ELISA, Micro screen
HBsAg ELISA, Innova HCV ELISA, HIV-EIA Comb and
HCV-Comb.It was found that the kit efficiency didn’t varies sig-
nificantly among three different kit companies and their
lots in all the cases except for HCV ELISA showing sta-
tistically significant variation (p < 0.01) among three kit
types. According to present study, Hepacard, Combaids
RS- Advantage-HIV, Crystal HBsAg, Signal HCV, SD
BIOLINE HIV ½ 3.0 Rapid, SD BIOLINE HBsAg Rapid
and SD BIOLINE HCV Rapid are the recommended
rapid kits demonstrating good performance whereas,
Microlisa HIV, ERBA LISA HIV1 + 2, ERBA LISA Hepa-
titis B, ERBA LISA HCV and Hepalisa (HBsAg) are most
acceptable ELISA kits with no false positive results. It is
needed to mention that present study was performed
with serum samples; therefore, performance of rapid
tests may vary if whole blood sample is used as done in
the point of care. As per overall results decipher, rapid
tests are more acceptable than ELISA for its specificity
But, ELISA proved to be more superior to rapid tests in
terms of sensitivity. In case of diagnosis of infectious dis-
ease, discordant results may have serious consequences
among the patients as it causes unnecessary mental stress
and tension. For proper diagnosis of infection as well as
disease management and prevention, identification of ap-
propriate test kit is necessary. According to this kit evalu-
ation, a higher number of false positive results obtained
in Microlisa HCV, Innova HCV ELISA and Microscreen
HBsAg ELISA which is really a matter of concern. Again,
false negative results leave a threat of silent transmission
and spreading of diseases among people as produced by
rapid HCV-comb and HIV-comb assay and also create
an urge for sensitive assays like ELISA. Therefore, in re-
source poor setting where ELISA is unavailable, practice
of using rapid kits for blood banks may lead to spread of
the deadly infection.
The HIV and HCV kits detect only IgG and thus miss
the IgM which is a critical marker of early infection.
Testing with these kits might lead to false negative for
samples of recent infection. Therefore, the tests are sub-
ject to the serious limitation which might affect a small
fraction of samples analyzed. Kits able to capture both
IgM and IgG needed to be developed to reduce the
chance of false negative and eventually helping in fight
against the pathogens.
Conclusions
Commercially available ELISA is good for screening of
HIV, HBV and HCV infections but rapid tests, as it is hav-
ing higher specificity, may be used further for detection of
false positive samples. In blood bank perspective, ELISA
seems the appropriate assay for the screening. Improve-
ment of sensitivity of rapid kit, which is attainable as evi-
dent in most of the kits evaluated, will help resource poor
setting. A regular mechanism of kit evaluation will help
ensuring availability of quality commercial kits.
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The study was carried out at NACO-National Reference
Laboratory at National Institute of Cholera and Enteric
Diseases, Indian Council of Medical Research, Kolkata,
India, which is a designated laboratory for evaluation of
diagnostic kits. Three different set of 100 member sera
panels were used for evaluation of commercially avail-
able ELISA and rapid kits in India, for HIV, HBsAg and
HCV. Characterization of sera panel was done by evalu-
ation of individual serum by two commercially available
ELISA kits, a rapid assay and a confirmatory western blot
assay / recombinant immuno-blot assay (RIBA)/ PCR as
detailed in Table 4. Sample reactive in all the assays were
defined as positive member in the panel and a negative
member was non-reactive in all the assays. All three sera
panels contain low positive sera that have shown uniform
results in all assays used for their validation.
Commercially available ELISA kits evaluated were
Microlisa- HIV, Hepalisa for HBsAg and HCV Microlisa-
manufactured by J. Mitra & Co. Pvt. Ltd, New Delhi,
India; Enzaids HIV 1 + 2 ELISA, Micro screen HBsAg
ELISA and Innova HCV ELISA - manufacturer Span
Diagnostics Ltd., Surat, India and ERBA LISA HIV 1 + 2,
ERBA LISA HEPATITIS B and ERBA LISA HEPATITIS
C- manufacturer Transasia Biomedicals Ltd. Mumbai,
India. The Rapid kits evaluated were HIV-EIA Comb,
Hepacard and HCV-Comb- J. MITRA & CO. PVT. LTD,
New Delhi, India; Combaids RS- Advantage-HIV, Crystal
HBsAg and Signal HCV Ver. 2.0- Span Diagnostics Ltd.
Surat, India and SD BIOLINE HIV ½ 3.0 Rapid, SD
BIOLINE HBsAg Rapid and SD BIOLINE HCV Rapid-
manufactured by Standard diagnostics INC, Haryana,
India. The kits selected in this study were most fre-
quently used in ICTCs and blood banks for detection
of HIV, HBsAg and HCV as well as were approved by
Central Drug Standard Control Organization for Blood
Banks [26]. Three lots for each ELISA and rapid kit-
types have been evaluated and their specifications were
detailed in Table 5. Manufacturer’s instructions and kit
literature were strictly followed for validation of assay.
Performance of kits for each lot was evaluated in terms of
sensitivity, specificity, positive predictive value, negativeTable 4 Characterization of panel sera for HIV, HBV and HCV
Name of
Panel ELISA
HIV Sera Panel ELISA 1: Vironostika HIV Ag/ Ab (BIOMERIEUX) ELISA 2:
Genescreen HIV 1/ 2, version 2. (Bio-Rad Laboratories)
HBV Sera Panel ELISA 1: Hepanostika HBsAg Ultra (BIOMERIEUX) ELISA 2:
MONOLISA HBsAg ULTRA (Bio-Rad Laboratories)
HCV Sera Panel ELISA 1: Ortho 3.0 Enhanced SAVe (Ortho Clinical Diagnos
ELISA 2: Monolisa anti-HCV Plus (Bio-Rad Laboratories)predictive value and efficiency which can be defined as
follows:
 Sensitivity = It is the ability of an assay to detect
truly infected individuals and very small amounts of
analyte. It can be calculated by following formula:
Sensitivity ¼ True Positives= True Positivesð½
þ False NegativesÞ X 100
 Specificity = It is the ability of an assay to correctly
identify all the uninfected individuals and there
should be no false positives. It can be calculated by
following formula:
Specificity ¼ True Negatives= True Negativesð½
þ False PositivesÞ X 100
 Positive Predictive Value (PPV) = It is the ability of a
test to identify actually infected individuals among
all persons giving a positive result with the kit being
used. It is calculated by following formula:
PPV ¼ True Positives= True Positivesð½
þ False PositivesÞ X 100
 Negative Predictive Value (NPV) = It is the ability of
a test to identify correctly the real non infected
individuals among all persons giving a negative
result with the kit being used. It is calculated by
following formula:
NPV ¼ True Negatives= True Negativesð½
þ False NegativesÞ X 100
 Efficiency = It is the overall ability of a test to
correctly identify all positives as positive and all
negatives as negative. This is also referred to as
‘accuracy’. It is calculated as follows
Efficiency ¼ True positivesþ True Negativesð Þ½
= True Positivesþ False Negativesð
þ True Negativesþ False PositivesÞ X 100T
ticest Details
Rapid Test Confirmatory Test
HIV Tri-Dot (J. Mitra & Co.
Pvt. Ltd.)






s) HCV TRI-DOT (J. Mitra & Co.
Pvt. Ltd.)
Western Blot: RIBA (Recombinant
Immuno-Blot assay)- CHIRON RIBA
HCV 3.0 SIA
Table 5 Specification characteristics of ELISA and rapid kits used for evaluation
Kit Type Kit Name Company Name Kit Specifications Detectable
Ag/Ab
HIV ELISA Microlisa-HIV J. Mitra & Co. Pvt Ltd. Indirect ELISA, recombinant antigens for HIV-1: gp41,
C-terminus of gp120; for HIV-2: gp36 used in MWP.
IgG
Enzaids HIV 1 + 2 ELISA SPAN Diagnostics Ltd. Indirect ELISA, a combination of recombinant and
synthetic peptides, derived from immuno-dominant
regions of HIV-1 (gp120, gp41) and HIV-2 (gp36)
used in MWP.
IgG
ERBA LISA HIV 1 + 2 Transasia Biomedicals Ltd. Indirect ELISA, synthetic peptide of HIV 1 & 2 coated
onto MWP.
IgG
HBsAg ELISA Hepalisa J. Mitra & Co. Pvt Ltd. Direct sandwich, microwell plates coated with
immobilized HBsAg antibodies
HBsAg
Microscreen HBsAg ELISA SPAN Diagnostics Ltd. Direct non-competitive ELISA, microwell plates coated
with immobilized HBsAg antibodies
HBsAg
ERBA LISA HEPATITIS B Transasia Biomedicals Ltd. Sandwich method, microwell plates coated with
immobilized HBsAg antibodies
HBsAg
HCV ELISA Microlisa HCV J. Mitra & Co. Pvt Ltd. Indirect ELISA, 3rd generation tests and utilizes
recombinant antigens
from CORE, E1, E2, NS3, NS4 and NS5 genomic regions
IgG
Innova HCV ELISA SPAN Diagnostics Ltd. Indirect ELISA, 3rd generation test with highest
sensitivity (100%) ensured by use of recombinant
antigens from core, E1, E2, NS3, NS4 & NS5
genomic regions.
IgG
ERBA LISA HEPATITIS C Transasia Biomedicals Ltd. Indirect ELISA, 3rd generation tests, utilizes a
combination of antigens
from CORE, NS3, NS4 and NS5 genomic regions
IgG
HIV RAPID HIV Comb J. Mitra & Co. Pvt Ltd. Dot Immunoassay, utilizes recombinant antigens for
HIV-1: gp41, C-terminus of gp120; for HIV-2: gp36.
IgG
Combaids-RS Advantage SPAN Diagnostics Ltd. Dot Immunoassay, a combination of recombinant
and synthetic peptides from immuno-dominant
regions of HIV-1 (gp120, gp41) & HIV-2 (gp36).
IgG
SD BIOLINE HIV ½ 3.0 Standard Diagnostics, INC Rapid immunochromatographic tests, membrane
strip precoated with recombinant HIV-1 capture
antigen (gp41, p24) on test band 1 region and
with recombinant HIV-2 capture antigen (gp36)
on test band 2.
IgG
HBsAg RAPID HEPACARD J. Mitra & Co. Pvt Ltd. One step, rapid, visual and qualitative
immunochromatographic assay based on the
antigen capture or “sandwich” principle, utilizes
monoclonal antibodies for HBsAg.
HBsAg
Crystal HBsAg SPAN Diagnostics Ltd. One step, rapid visual immunochromatographic
tests for qualitative detection of Hepatitis B surface
antigen (HBsAg), utilizes highly specific monoclonal
antibodies ensure no cross reactivity with HAV
and HCV
HBsAg
SD BIOLINE HBsAg Standard Diagnostics,
INC
One step, rapid, visual and qualitative
immunochromatographic assay, membrane strip
precoated with mouse monoclonal anti-HBs capture
antibody on test band.
HBsAg
HCV RAPID HCV-Comb J. Mitra & Co. Pvt Ltd. 4th generation Dot Immunoassay, utilizes a unique
combination of modified HCV antigens from the
putative core, NS3, NS4 & NS5 genomic regions
IgG
Signal HCV SPAN Diagnostics Ltd. 3rd generation immuno-dot test comprising of
recombinant antigens from core, E1,E2,NS3,NS4
& NS5 genomic regions of HCV
IgG
SD BIOLINE HCV Standard Diagnostics,
INC
One step, rapid, visual and qualitative
immunochromatographic assay, membrane strip
precoated with recombinant HCV capture antigen
(CORE, NS3, NS4 and NS5) on test band.
IgG
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http://www.virologyj.com/content/9/1/290The evaluation process maintained unbiased following a
double-blind procedure (separate personnel adopted for
pre-analytical and analytical/testing sections and finally
both of them involved in result verification for test valid-
ation, but final analysis of result was done independently
by the Lab In-charge). Information regarding status of
panel samples has been restricted from testing personnel.
Sera used in this study were obtained anonymously
from volunteer attendees of the Integrated Counseling
and Testing Centre following informed consent from
each individual as per protocol approved by the Institu-
tional Ethics Committee, National Institute of Cholera
and Enteric Diseases.
Statistical analysis
Confidence Interval (CI) was used to address precision
of the proportion estimates and the degree of confidence
was set to 95% [22]. Analysis of variance (ANOVA) also
has been performed among different kit companies as
well as in lots to enquire the significance of variations in
kit efficiency.
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